



# ASX Announcement

For immediate release

25 June 2021

## Resignation of Director

CSL Limited (ASX:CSL; USOTC:CSLLY) advises that the CSL Board of Directors has regretfully accepted the resignation of Mr Abbas Hussain as an independent Non-Executive Director, effective immediately. Mr Hussain submitted his resignation after being appointed as the Chief Executive Officer of Vifor Pharma Group, a global speciality pharmaceuticals group based in Switzerland.

Mr Hussain joined CSL as an independent Non-Executive Director in 2017 and has served on the Human Resources and Remuneration Committee, and the Innovation and Development Committee.

CSL's Chair, Dr Brian McNamee AO said "I would like to thank Abbas for his contribution to CSL over the last four years. His global biopharmaceutical experience and deep understanding of manufacturing and product development have meant he brought deep strategic and industry insight to CSL".

The CSL Board and management team wish to thank Abbas for his contribution to the Company and wish him every success in his new role.

Authorised by  
**Fiona Mead**  
Company Secretary

## FURTHER INFORMATION

For further information, please contact:

### Investors:

Stephen McKeon  
Associate Director Investor Relations  
CSL Limited  
Telephone: +61 402 231 696  
Email: [Stephen.Mckeon@csl.com.au](mailto:Stephen.Mckeon@csl.com.au)

### Media:

Jimmy Baker  
Communications, Asia Pacific  
CSL Limited  
+61 45 090 9211  
Email: [jimmy.baker@csl.com.au](mailto:jimmy.baker@csl.com.au)